Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease
Abstract Failures in Alzheimer's disease (AD) drug trials highlight the need to further explore disease mechanisms and alterations of biomarkers during the development of AD. Using cross‐sectional data from 377 participants in the BioFINDER study, we examined seven cerebrospinal fluid (CSF) and...
Main Authors: | Sebastian Palmqvist, Philip S Insel, Erik Stomrud, Shorena Janelidze, Henrik Zetterberg, Britta Brix, Udo Eichenlaub, Jeffrey L Dage, Xiyun Chai, Kaj Blennow, Niklas Mattsson, Oskar Hansson |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-12-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.201911170 |
Similar Items
-
Towards a unified protocol for handling of CSF before β-amyloid measurements
by: Shorena Janelidze, et al.
Published: (2019-07-01) -
Effects of surgery and propofol-remifentanil total intravenous anesthesia on cerebrospinal fluid biomarkers of inflammation, Alzheimer’s disease, and neuronal injury in humans: a cohort study
by: Andreas Pikwer, et al.
Published: (2017-09-01) -
Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
by: Laia Montoliu-Gaya, et al.
Published: (2021-08-01) -
The cerebrospinal fluid biomarker ratio Aβ42/40 identifies amyloid positron emission tomography positivity better than Aβ42 alone in a heterogeneous memory clinic cohort
by: Amft, M., et al.
Published: (2022) -
Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
by: Claudia Cicognola, et al.
Published: (2021-03-01)